BAJAJ BROKING

Notification close image
No new Notification messages
card image
3B Films IPO is Open!
Apply for the 3B Films IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr. Reddy’s Laboratories Q2 Results FY24-25 Highlights, Revenue and PAT Analysis

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Dr. Reddy’s Laboratories delivered a strong Q2 FY24-25, showcasing substantial revenue growth with consolidated revenue reaching ₹80,162 million. However, profit after tax saw a slight decline. Explore detailed insights and segment breakdown.

Key Highlights

  • Revenue: ₹80,162 million, up 17% YoY
  • Profit After Tax (PAT): ₹13,415 million, down 9% YoY
  • EBITDA: ₹22,803 million, showcasing a resilient operational performance
  • EPS: Basic earnings per share at ₹15.07 for Q2 FY24-25

DR. REDDY S LABORATORIES

Trade

1247.7-3.50 (-0.27 %)

Updated - 02 June 2025
1251.50day high
DAY HIGH
1232.50day low
DAY LOW
1139977
VOLUME (BSE)

Quarterly - Dr. Reddy's Q2 Results FY24-25

Dr. Reddy’s Laboratories reported consolidated revenue of ₹80,162 million for Q2 FY24-25, a year-over-year increase of 17% and a quarter-over-quarter growth of 4%. Despite higher costs, the gross profit margin remained strong, supporting Dr. Reddy's growth across its generics and emerging markets segments.

The net profit after tax reached ₹13,415 million, a 9% decline YoY, mainly due to one-time expenses, including acquisition-related costs and tax adjustments. This stable financial performance, combined with strategic investments in research and partnerships, underscores Dr. Reddy’s ongoing commitment to operational efficiency and expansion into emerging markets.

Segment Highlights

  1. Global Generics: Revenue from the Global Generics segment was ₹71,576 million, reflecting a 17% YoY growth, mainly driven by increased sales volumes and new product launches.
  2. Pharmaceutical Services and Active Ingredients (PSAI): This segment delivered revenue of ₹8,407 million, boosted by higher volumes and an enhanced product mix.
  3. Others: The 'Others' segment contributed ₹179 million, indicating a drop from the previous year due to strategic focus on core areas.

Sector Expectations for Dr. Reddy's Q2 Results FY24-25

Dr. Reddy’s Q2 results exceeded industry expectations, with a substantial increase in revenue from its generics segment, especially in North America and emerging markets. This growth aligns with the sector’s robust demand for generic drugs, while slight declines in profit were anticipated due to higher SG&A and R&D investments.

Management Commentary

G V Prasad, Co-Chairman & MD of Dr. Reddy’s, noted, "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation."

Financial Table:

Metric

Q2 FY24-25

Q1 FY24-25

Q2 FY23-24

Revenue (₹ million)

80,162

76,727

68,802

Gross Profit (₹ million)

47,769

46,344

40,368

EBITDA (₹ million)

22,803

21,599

21,813

PAT (₹ million)

13,415

13,920

14,800

EPS (₹)

15.07

16.72

17.80

Selling & Administrative Expenses

23,007

22,691

18,795

R&D Expenses (₹ million)

7,271

6,193

5,447

Check out Dr Reddy's Lab's past performances in previous quarters and financial years.

Conclusion

Dr. Reddy’s Q2 results for FY24-25 demonstrate a solid performance with significant revenue growth across core segments. Despite challenges from rising costs and tax adjustments, the company has maintained a stable profit margin, underscoring its resilience and strategic focus. With new acquisitions, partnerships, and a strong presence in emerging markets, Dr. Reddy’s is well-positioned for sustained growth in the coming quarters.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|